Skip to main content
Log in

Experience of a 40-day (6 week) LMWH treatment for isolated distal deep vein thrombosis

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Clinical significance of distal deep vein thrombosis (DVT) is important as it can potentially result in pulmonary embolism (PE), DVT extension, DVT recurrence and post-thrombotic syndrome (PTS). Controversy remains about the necessity and modalities of anticoagulation in all distal DVT. Evaluation of the efficiency of a 40-day weight-based low molecular weight heparin (LMWH) treatment in a cohort of 119 consecutive patients with distal DVT. Compression ultrasonography of the lower limb was performed initially for diagnosis as well as at the end of the treatment to identify persistence or resolution of the blood clot. A 3-month follow-up estimated the rates of PE, DVT recurrence, DVT extension, PTS and bleeding. Risk factors for DVT were considered to evaluate a possible correlation between them and the outcomes. In 71.4% of the patients the blood clot was totally dissolved and thrombus persistence was statistically associated with the number of initially involved veins. DVT recurrence occurred in 5% of patients and was also associated with the number of initial clotted veins. DVT extension and PTS rates were present in 1.7% and 3.4% respectively and no patient was diagnosed with PE or bleeding. This retrospective study including a limited number of patients and no control group supports that a 40-day weight-based LMWH treatment after distal DVT seems to be efficient when one single vein is initially affected whereas for multiple vein distal DVT and to avoid potential DVT recurrence, longer than 6 weeks of anticoagulant treatment is required. Our results support safety of the treatment, its potential to prevent DVT extension and the occurrence of PE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Tapson VF (2008) Acute pulmonary embolism. N Engl J Med 358(10):1037–1052

    Article  CAS  Google Scholar 

  2. Farrell JJ et al (2016) Incidence and interventions for post-thrombotic syndrome. Cardiovasc Diagn Ther 6(6):623–631

    Article  Google Scholar 

  3. Vazquez SR, Kahn SR (2010) Postthrombotic syndrome. Circulation 121(8):e217–e219

    Article  Google Scholar 

  4. Kearon C, Akl EA (2014) Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism. Blood 123(12):1794–1801

    Article  CAS  Google Scholar 

  5. Kearon C et al (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 133(6 Suppl):454S–545S

    Article  CAS  Google Scholar 

  6. Kearon C et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e496S

    Article  CAS  Google Scholar 

  7. National CGCU (2012) Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing

  8. Nicolaides AN et al (2013) Prevention and treatment of venous thromboembolism–International Consensus Statement. Int Angiol 32(2):111–260

    CAS  PubMed  Google Scholar 

  9. Kearon C et al (2016) Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 149(2):315–352

    Article  Google Scholar 

  10. Rabinovich A, Kahn SR (2014) How to predict and diagnose postthrombotic syndrome. Pol Arch Med Wewn 124(7–8):410–416

    PubMed  Google Scholar 

  11. Yates D, Moore D, McCabe G (1999) The practice of statistics. W. H. Freeman, New York

    Google Scholar 

  12. Barco S et al (2019) Impact of sex, age, and risk factors for venous thromboembolism on the initial presentation of first isolated symptomatic acute deep vein thrombosis. Thromb Res 173:166–171

    Article  CAS  Google Scholar 

  13. Galanaud JP et al (2009) Comparison of the clinical history of symptomatic isolated distal deep-vein thrombosis vs. proximal deep vein thrombosis in 11 086 patients. J Thromb Haemost 7(12):2028–2034

    Article  CAS  Google Scholar 

  14. Ferrara F et al (2006) Optimal duration of treatment in surgical patients with calf venous thrombosis involving one or more veins. Angiology 57(4):418–423

    Article  Google Scholar 

  15. Galanaud JP et al (2014) Incidence and predictors of venous thromboembolism recurrence after a first isolated distal deep vein thrombosis. J Thromb Haemost 12(4):436–443

    Article  Google Scholar 

  16. Donadini MP et al (2017) Long-term recurrence of venous thromboembolism after short-term treatment of symptomatic isolated distal deep vein thrombosis: a cohort study. Vasc Med 22(6):518–524

    Article  Google Scholar 

  17. Franco L et al (2017) Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis. J Thromb Haemost 15(6):1142–1154

    Article  CAS  Google Scholar 

  18. Monreal M et al (1992) Deep venous thrombosis and the risk of pulmonary embolism. A systematic study. Chest 102(3):677–681

    CAS  PubMed  Google Scholar 

  19. Righini M et al (2016) Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial. Lancet Haematol 3(12):e556–e562

    Article  Google Scholar 

  20. Schwarz T et al (2010) Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study. J Vasc Surg 52(5):1246–1250

    Article  Google Scholar 

  21. Schwarz T et al (2001) Therapy of isolated calf muscle vein thrombosis with low-molecular-weight heparin. Blood Coagul Fibrinolysis 12(7):597–599

    Article  CAS  Google Scholar 

  22. Palareti G et al (2010) Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. Thromb Haemost 104(5):1063–1070

    CAS  PubMed  Google Scholar 

  23. Robert-Ebadi H, Righini M (2017) Management of distal deep vein thrombosis. Thromb Res 149:48–55

    Article  CAS  Google Scholar 

  24. Palareti G (2014) How I treat isolated distal deep vein thrombosis (IDDVT). Blood 123(12):1802–1809

    Article  CAS  Google Scholar 

  25. Poudel SK et al (2020) Clinical outcomes of isolated distal deep vein thrombosis versus proximal venous thromboembolism in cancer patients: The Cleveland Clinic experience. J Thromb Haemost 18(3):651–659

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Konstantinos Asonitis.

Ethics declarations

Conflict of interest

The authors state that they have no conflict of interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Asonitis, K., Charvalos, E., Lambert, C. et al. Experience of a 40-day (6 week) LMWH treatment for isolated distal deep vein thrombosis. J Thromb Thrombolysis 50, 837–843 (2020). https://doi.org/10.1007/s11239-020-02089-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-020-02089-5

Keywords

Navigation